| P2093 | author name string | Yu Wang | |
| | Lin Wang | |
| | Wei Zhang | |
| | Fang Wang | |
| | Xiaojun Zhang | |
| | Yunbo Jiang | |
| | Yuanji Xu | |
| | Jiyun Yu | |
| | Jinqi Yan | |
| P2860 | cites work | Intraarticular gene delivery of CTLA4-FasL suppresses experimental arthritis. | Q50502021 |
| | CTLA4-FasL fusion product suppresses proliferation of fibroblast-like synoviocytes and progression of adjuvant-induced arthritis in rats | Q56898256 |
| | Prolongation of corneal allograft survival by CTLA4-FasL in a murine model | Q56901047 |
| | Furin at the cutting edge: from protein traffic to embryogenesis and disease | Q24670432 |
| | Isolation and characterization of phage-displayed single chain antibodies recognizing nonreducing terminal mannose residues. 2. Expression, purification, and characterization of recombinant single chain antibodies | Q33267995 |
| | Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate | Q34547988 |
| | Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis | Q35132863 |
| | Gene therapy as a therapeutic approach for the treatment of rheumatoid arthritis: innovative vectors and therapeutic genes | Q36410818 |
| | Gene therapy for rheumatoid arthritis: recent advances | Q37108329 |
| | Gene therapy of the rheumatic diseases: 1998 to 2008. | Q37207021 |
| | Stable expression of native Coagulation factor VIII using the 2A self-processing sequence and furin cleavage site | Q39497928 |
| | Combination of the 2A/furin technology with an animal component free cell line development platform process | Q39704805 |
| | Analysis of IgG heavy chain to light chain ratio with mutant Encephalomyocarditis virus internal ribosome entry site | Q40064496 |
| | Stable antibody expression at therapeutic levels using the 2A peptide | Q40434248 |
| | Improved vectors for stable expression of foreign genes in mammalian cells by use of the untranslated leader sequence from EMC virus | Q40506219 |
| | CTLA-4. FasL induces alloantigen-specific hyporesponsiveness | Q40641499 |
| | CTLA-4-Fas ligand functions as a trans signal converter protein in bridging antigen-presenting cells and T cells | Q40815613 |
| | IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector | Q40863150 |
| | Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study | Q43209177 |
| | Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study. | Q43632894 |
| | Co-translational, intraribosomal cleavage of polypeptides by the foot-and-mouth disease virus 2A peptide | Q45729586 |
| | Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist | Q45744151 |
| | Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector | Q45874327 |
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 6301-6314 | |
| P577 | publication date | 2013-03-06 | |
| P1433 | published in | Applied Microbiology and Biotechnology | Q13553694 |
| P1476 | title | Design, expression and characterization of a novel coexpression system of two antiarthritic molecules | |
| P478 | volume | 97 | |